Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 10/20 | 0.42 |
| ▸ | CA1 | P00915 | 7/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5186164 | 1.00 | KIF11 (0.50) | KIF11CA2CA1CA12CA9 | |
| SCHEMBL6155949 | 1.00 | KIF11 (0.50) | KIF11CA2CA1CA12CA9 | |
| SCHEMBL6561643 | 0.86 | ALDH1A1 (0.39) | KIF11CA2CA1CA12CA9 | |
| SCHEMBL5186197 | 0.85 | KIF11 (0.41) | KIF11PTGES2 | |
| SCHEMBL5187874 | 0.85 | CYP2C19 (0.44) | KIF11CA2CA1CA12CA9 | |
| SCHEMBL5186198 | 0.82 | CA12 (0.38) | KIF11CA2CA1CA12CA9 | |
| SCHEMBL5186139 | 0.82 | KIF11 (0.39) | KIF11 | |
| SCHEMBL5186196 | 0.82 | KIF11 (0.39) | KIF11PTGES2 | |
| SCHEMBL5186056 | 0.81 | KIF11 (0.44) | KIF11CA2CA1CA12CA9 | |
| SCHEMBL5186063 | 0.81 | RXRA (0.40) | KIF11KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330233-B1 | METHOD OF TREATING STROKE | LILLY CO ELI (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040063680-A1 | Method of treating stroke | CLEMENS JAMES ALLEN (US) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063680-A1 | Method of treating stroke | ASAH2, PCSK7, PCSK9 | KIF11 338/4885CA2 233/4885CA1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.